Patient demographic and graft characteristics
| Characteristic . | Letermovir prophylaxis patients (n = 28) . | Historic control patients (n = 62)∗ . |
|---|---|---|
| Age, median (range), y | 47 (26-65) | 50 (23-66) |
| Weight, median (range), kg | 79 (54-115) | 76 (47-123) |
| Male | 13 (46%) | 27 (44%) |
| Diagnosis | ||
| Acute leukemia | 21 (75%) | 45 (73%) |
| AML | 13 (46%) | 36 (58%) |
| ALL | 7 (25%) | 7 (11%) |
| Biphenotypic | 1 (4%) | 2 (3%) |
| MDS/MPN | 5 (18%) | 7 (11%) |
| Non-Hodgkin lymphoma | 2 (7%) | 9 (15%) |
| Other | 0 | 1 (2%) |
| CB-recipient 8-allele HLA match, median (range) | 4/8 (3-6) | 5/8 (2-7) |
| Infused TNC dose × 107/kg/unit, median (range) | 2.4 (1.4-6.5) | 2.5 (1.2-6.0) |
| Infused viable CD34+ cell dose × 105/kg/unit, median (range) | 1.8 (0.5-7.7) | 1.3 (0.3-8.3) |
| GVHD prophylaxis | ||
| CSA/MMF | 0 | 62 (100%) |
| CSA/MMF/tocilizumab | 28 (100%) | 0 |
| Characteristic . | Letermovir prophylaxis patients (n = 28) . | Historic control patients (n = 62)∗ . |
|---|---|---|
| Age, median (range), y | 47 (26-65) | 50 (23-66) |
| Weight, median (range), kg | 79 (54-115) | 76 (47-123) |
| Male | 13 (46%) | 27 (44%) |
| Diagnosis | ||
| Acute leukemia | 21 (75%) | 45 (73%) |
| AML | 13 (46%) | 36 (58%) |
| ALL | 7 (25%) | 7 (11%) |
| Biphenotypic | 1 (4%) | 2 (3%) |
| MDS/MPN | 5 (18%) | 7 (11%) |
| Non-Hodgkin lymphoma | 2 (7%) | 9 (15%) |
| Other | 0 | 1 (2%) |
| CB-recipient 8-allele HLA match, median (range) | 4/8 (3-6) | 5/8 (2-7) |
| Infused TNC dose × 107/kg/unit, median (range) | 2.4 (1.4-6.5) | 2.5 (1.2-6.0) |
| Infused viable CD34+ cell dose × 105/kg/unit, median (range) | 1.8 (0.5-7.7) | 1.3 (0.3-8.3) |
| GVHD prophylaxis | ||
| CSA/MMF | 0 | 62 (100%) |
| CSA/MMF/tocilizumab | 28 (100%) | 0 |
CML, chronic myeloid leukemia; MDS, myelodysplastic syndromes; MPD, myeloproliferative disorder; TNC, total nucleated cell.
In 29 historic control patients, CB grafts were supplemented with haplo-identical CD34+ cells as previously described.25